Feb 25 (Reuters) - Danish drugmaker Novo Nordisk has partnered with U.S.-based Vivtex Corp in a deal worth up to $2.1 billion ...

In this week’s edition of InnovationRx, we look at cheaper biologic drugs, Novo Nordisk’s $2 billion next-gen obesity drug deal, new ways of fighting cancer, and more.

Novo Nordisk (CPSE:NOVO B) has entered a new $2.1b partnership with Vivtex to develop next generation oral biologic drugs for obesity and diabetes. The collaboration targets oral versions of medicines ...

The Food and Drug Administration said it will take steps to speed up the process of developing generic versions of complex biological drugs, in a bid to increase cheaper competition for expensive ...

The Food and Drug Administration said it will be taking steps to speed up the approval process for developing generic biological drugs, an effort aimed at increasing cheaper competition among ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

DUBLIN--(BUSINESS WIRE)--The "Biological Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Biological Drugs was estimated at ...

New biologic drugs for chronic obstructive pulmonary disease (COPD) are finally here, said Stephen Rennard, MD, in a presentation in a session on new drugs at the 2024 GOLD International COPD ...

Biologic drugs have improved how doctors treat serious illnesses. Instead of being made from chemicals, biologics are made from organic materials and grown in living cells. Biologic drugs are used ...

As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened regulatory scrutiny, the role of the top pharmaceutical API manufacturer has taken on ...

The Biologics Price Competition and Innovation Act of (BPCI Act) of 2009 granted responsibility to the FDA for review and approval of a new class of pharmaceuticals referred to as “Biosimilars.” (1) ...

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant ...